PROTAC 44 at approximately 100 nM was able to efficiently degrade both mutant EGFRL858R + T790M and ALK fusion proteins (the two most important targets in non-small-cell lung cancer). The gene discussed is ALK; the disease is non-small cell lung carcinoma.